DealsJun 22, 2026, 07:32 AM
Nuvectis Pharma Licenses Two Clinical-Stage Compounds from Haisco
AI Summary
Nuvectis Pharma announced a strategic portfolio expansion through a license agreement with Haisco Pharmaceutical Group for exclusive ex-China rights to two clinical-stage compounds, NXP100 and NXP200. This deal transforms Nuvectis into a late-stage clinical development company, expanding its pipeline into complement-mediated diseases and enhancing its oncology product offerings. Haisco will receive up to $40 million in upfront and near-term payments, with potential for up to $1.421 billion in additional development, regulatory, and commercial milestone payments, plus tiered royalties.
Key Highlights
- Nuvectis licensed exclusive ex-China rights to two clinical-stage compounds from Haisco.
- Haisco will receive up to $40 million in upfront and near-term payments.
- Haisco is eligible for up to $1.421 billion in additional milestone payments.
- NXP100 (CFBi) has two Marketing Authorization Applications under review in China for PNH.
- NXP100 is in an ongoing Phase 3 trial for Immunoglobulin A Nephropathy (IgAN).
- NXP200 (BRAFi) is in an ongoing Phase 1b study in China for BRAF-mutated malignancies.
- Composition of matter patents for NXP100 expire in 2043 and for NXP200 in 2042.
- The PNH market size is expected to exceed $5.0 billion in 2026.
Price Impact
More from NVCT